Zuvilix has a medicine called Elagolix sodium. It helps reduce moderate to severe pain caused by endometriosis, a condition where tissue similar to the lining inside the uterus grows outside it.
- Zuvilix comes in tablet form in strengths of 150 mg, and 200 mg.
- The tablets are packed in a PVC-Alu blister strip of 10 tablets.
Supexa OD contains the active substance edoxaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming. It works by blocking the activity of factor Xa, which is an important component of blood clotting.
Supexa OD is used in adults to:
- prevent blood clots in the brain (stroke) and other blood vessels in the body if you have a form of irregular heart rhythm called nonvalvular atrial fibrillation and at least one additional risk factor, such as heart failure, previous stroke or high blood pressure;
-treat blood clots in the veins of the legs (deep vein thrombosis) and in the blood vessels in the lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels in the legs and/or lungs.
Plecasoft (Plecanatide 3 mg Tablets) - The Next Generation Laxative, which is 8 times more potent than Uroguanylin, bind to guanylate cyclase-C (GC-C) receptor on the proximal luminal surface of the intestinal epithelium. By increasing cGMP concentration, it results in the secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel. This causes increased intestinal fluid, which softens the stool, accelerates intestinal transit, and decreases abdominal pain sensation. Plecasoft is approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults.
Zuventus has always been at the forefront in bringing innovation and excellence in Healthcare.
As part of this commitment to the medical fraternity & patients, Zuventus introduced a novel concept-based molecule, Trelagliptin (Trelaglip), a Once-Weekly Oral DPP4i for the management of Type 2 Diabetes Mellitus (T2DM), designed to address existing challenges in glycemic control & patient compliance.
Trelaglip makes a difference to QoL with Compliance & Control, available in 3 SKUs (100 MG, 50 MG & 25 MG)
Know More about Trelaglip
